ImmunityBio, Inc. - 8-K Filing

ImmunityBio's ANKTIVA® plus BCG met primary endpoint in Cohort A of QUILT-2.005 trial for BCG-naïve NMIBC (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)

SEC EDGAR · November 9, 2026, 11:33 UTC

Tickers: $IBRX

Read the full article at SEC EDGAR

Part of the story ImmunityBio, Inc. - 8-K Filing (2 articles)

More Regulatory news

Applied Aerospace & Defense, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 14:02 UTC
Palomar Holdings, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:02 UTC
UNITED GUARDIAN INC - 10-Q Filing SEC EDGAR · November 12, 2026, 14:00 UTC
Dare Bioscience, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 14:00 UTC
NEXGEL, INC. - 8-K Filing SEC EDGAR · November 12, 2026, 14:00 UTC
TEREX CORP - 8-K Filing SEC EDGAR · November 12, 2026, 14:00 UTC
Victory Capital Holdings, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:59 UTC
Nano Dimension Ltd. - 8-K Filing SEC EDGAR · November 12, 2026, 13:59 UTC
M-tron Industries, Inc. - 10-Q Filing SEC EDGAR · November 12, 2026, 13:56 UTC
M-tron Industries, Inc. - 8-K Filing SEC EDGAR · November 12, 2026, 13:55 UTC